$INBX
Inhibrx Biosciences, Inc.

2024 Q3 Form 10-Q Financial Statement

#000200791924000029 Filed on August 13, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2 2024 Q1
Revenue $0.00 $100.0K $0.00
YoY Change -100.0% 233.33% -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $7.804M $93.27M $9.870M
YoY Change -0.59% 1193.55% 55.68%
% of Gross Profit
Research & Development $38.89M $67.63M $63.60M
YoY Change 2.89% 98.3% 71.18%
% of Gross Profit
Depreciation & Amortization $760.0K $475.0K $360.0K
YoY Change 153.33% 61.02% 20.0%
% of Gross Profit
Operating Expenses $46.80M $161.0M $73.83M
YoY Change 1.84% 289.18% 68.63%
Operating Profit -$46.80M -$160.9M
YoY Change 2.12% 289.22%
Interest Expense $2.892M -$2.620M -$4.826M
YoY Change -149.61% -52.28% -5.0%
% of Operating Profit
Other Income/Expense, Net $2.933M $2.019B -$59.00K
YoY Change -2195.0% -35469.85% -15.71%
Pretax Income -$43.86M $1.858B -$78.71M
YoY Change -15.3% -4049.27% 60.9%
Income Tax $0.00 $2.000K
% Of Pretax Income 0.0%
Net Earnings -$43.86M $1.858B -$78.71M
YoY Change -15.3% -4048.85% 60.91%
Net Earnings / Revenue 1858011.0%
Basic Earnings Per Share -$2.84 $127.10
Diluted Earnings Per Share -$2.84 $125.50 -$1.44
COMMON SHARES
Basic Shares Outstanding 14.48M shares 14.62M shares
Diluted Shares Outstanding 15.47M shares 14.81M shares

Balance Sheet

Concept 2024 Q3 2024 Q2 2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $196.3M $226.9M $252.5M
YoY Change -41.79% 17.85% 7.76%
Cash & Equivalents $196.3M $226.9M $252.5M
Short-Term Investments
Other Short-Term Assets $748.0K $966.0K $19.02M
YoY Change -97.08% -90.8% 106.71%
Inventory
Prepaid Expenses
Receivables $455.0K $435.0K $171.0K
Other Receivables $672.0K $952.0K $2.867M
Total Short-Term Assets $207.4M $242.1M $274.5M
YoY Change -42.9% 19.06% 12.61%
LONG-TERM ASSETS
Property, Plant & Equipment $6.879M $7.605M $9.453M
YoY Change 9.19% 13.51% 39.01%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $6.712M $6.745M $4.586M
YoY Change 109.75% 110.78% 43.31%
Total Long-Term Assets $15.12M $16.36M $14.04M
YoY Change 60.81% 65.26% 41.81%
TOTAL ASSETS
Total Short-Term Assets $207.4M $242.1M $274.5M
Total Long-Term Assets $15.12M $16.36M $14.04M
Total Assets $222.6M $258.4M $288.6M
YoY Change -40.28% 21.21% 13.75%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $12.37M $13.02M $14.79M
YoY Change 56.58% 34.24% 35.71%
Accrued Expenses $29.89M $23.86M $53.45M
YoY Change 7.13% 10.98% 147.44%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $3.632M
YoY Change
Total Short-Term Liabilities $44.10M $39.05M $71.87M
YoY Change 23.17% 24.77% 120.46%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $204.6M
YoY Change -100.0% -100.0% 0.63%
Other Long-Term Liabilities $0.00 $0.00 $561.0K
YoY Change -100.0% -100.0% -79.22%
Total Long-Term Liabilities $0.00 $0.00 $205.1M
YoY Change -100.0% -100.0% -0.42%
TOTAL LIABILITIES
Total Short-Term Liabilities $44.10M $39.05M $71.87M
Total Long-Term Liabilities $0.00 $0.00 $205.1M
Total Liabilities $44.10M $39.05M $277.0M
YoY Change -81.86% -83.59% 16.1%
SHAREHOLDERS EQUITY
Retained Earnings -$58.30M -$14.40M
YoY Change
Common Stock $1.000K $1.000K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $178.5M $219.4M $11.57M
YoY Change
Total Liabilities & Shareholders Equity $222.6M $258.4M $288.6M
YoY Change -40.28% 21.21% 13.75%

Cashflow Statement

Concept 2024 Q3 2024 Q2 2024 Q1
OPERATING ACTIVITIES
Net Income -$43.86M $1.858B -$78.71M
YoY Change -15.3% -4048.85% 60.91%
Depreciation, Depletion And Amortization $760.0K $475.0K $360.0K
YoY Change 153.33% 61.02% 20.0%
Cash From Operating Activities -$30.28M -$57.36M -$63.05M
YoY Change -44.18% 35.6% 57.86%
INVESTING ACTIVITIES
Capital Expenditures $247.0K $1.215M $1.119M
YoY Change -69.51% 279.69% 5495.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$247.0K -$1.215M -$1.119M
YoY Change -69.51% 279.69% 5495.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 32.95M 38.73M
YoY Change -100.0% 3776.47% 10657.78%
NET CHANGE
Cash From Operating Activities -30.28M -57.36M -63.05M
Cash From Investing Activities -247.0K -1.215M -1.119M
Cash From Financing Activities 0.000 32.95M 38.73M
Net Change In Cash -30.53M -25.62M -25.44M
YoY Change -121.08% -38.66% -35.76%
FREE CASH FLOW
Cash From Operating Activities -$30.28M -$57.36M -$63.05M
Capital Expenditures $247.0K $1.215M $1.119M
Free Cash Flow -$30.53M -$58.57M -$64.17M
YoY Change -44.56% 37.43% 60.58%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q2 inhibrx Merger Exchange Ratio Pro Rate Basis Percentage
MergerExchangeRatioProRateBasisPercentage
0.25
CY2024Q2 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
952000 usd
CY2023Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
607000 usd
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
13810000 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
16656000 usd
CY2024Q2 us-gaap Assets Current
AssetsCurrent
242057000 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
295358000 usd
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7605000 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6419000 usd
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2011000 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2952000 usd
CY2024Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
6745000 usd
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3164000 usd
CY2024Q2 us-gaap Assets
Assets
258418000 usd
CY2023Q4 us-gaap Assets
Assets
307893000 usd
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
13021000 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
10954000 usd
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
23860000 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
43295000 usd
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2171000 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2063000 usd
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
39052000 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
56312000 usd
CY2024Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
0 usd
CY2023Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
206968000 usd
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1110000 usd
CY2024Q2 us-gaap Liabilities
Liabilities
39052000 usd
CY2023Q4 us-gaap Liabilities
Liabilities
264390000 usd
CY2024Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
15000000 shares
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
15000000 shares
CY2024Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2024Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2024Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000 shares
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
14475904 shares
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
14475904 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
47369511 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
47369511 shares
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
1000 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
5000 usd
CY2024Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
233768000 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
657232000 usd
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-14403000 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-613734000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
219366000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
43503000 usd
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
258418000 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
307893000 usd
us-gaap Revenues
Revenues
100000 usd
us-gaap Revenues
Revenues
47000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
131483000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
71492000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
103340000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13660000 usd
us-gaap Operating Expenses
OperatingExpenses
234823000 usd
us-gaap Operating Expenses
OperatingExpenses
85152000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-234723000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-85105000 usd
us-gaap Nonmonetary Transaction Gain Loss Recognized On Transfer
NonmonetaryTransactionGainLossRecognizedOnTransfer
2021498000 usd
us-gaap Nonmonetary Transaction Gain Loss Recognized On Transfer
NonmonetaryTransactionGainLossRecognizedOnTransfer
0 usd
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
13491000 usd
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
15468000 usd
inhibrx Interest Income Nonoperating
InterestIncomeNonoperating
6045000 usd
inhibrx Interest Income Nonoperating
InterestIncomeNonoperating
4897000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-26000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-287000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2014026000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-10858000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
1779303000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-95963000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
5000 usd
us-gaap Net Income Loss
NetIncomeLoss
1779301000 usd
us-gaap Net Income Loss
NetIncomeLoss
-95968000 usd
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
125.93
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-8.80
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
122.75
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-8.80
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14129000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10902000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14495000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
10902000 shares
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
43503000 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6397000 usd
CY2024Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
40378000 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-78710000 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
11568000 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
46174000 usd
CY2024Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
31300000 usd
CY2024Q2 us-gaap Stockholders Equity Note Spinoff Transaction
StockholdersEquityNoteSpinoffTransaction
-1743729000 usd
CY2024Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
16042000 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
1858011000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
219366000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
58057000 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5636000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
356000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-48916000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
15133000 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6253000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
854000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-47052000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-24812000 usd
us-gaap Net Income Loss
NetIncomeLoss
1779301000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
836000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
589000 usd
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
2065000 usd
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
2413000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
52571000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
11889000 usd
inhibrx Noncash Operating Lease Expense
NoncashOperatingLeaseExpense
941000 usd
inhibrx Noncash Operating Lease Expense
NoncashOperatingLeaseExpense
864000 usd
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0 usd
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-2000 usd
inhibrx Nonmonetary Transaction Gain Loss Recognized On Transfer Net
NonmonetaryTransactionGainLossRecognizedOnTransferNet
1998809000 usd
inhibrx Nonmonetary Transaction Gain Loss Recognized On Transfer Net
NonmonetaryTransactionGainLossRecognizedOnTransferNet
0 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
100000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
84000 usd
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
345000 usd
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
0 usd
us-gaap Increase Decrease In Due From Related Parties
IncreaseDecreaseInDueFromRelatedParties
164000 usd
us-gaap Increase Decrease In Due From Related Parties
IncreaseDecreaseInDueFromRelatedParties
-14000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3446000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
4131000 usd
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
3581000 usd
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
0 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
21472000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
792000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
29853000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
2327000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-1002000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-903000 usd
inhibrx Increase Decrease Contract With Customer Liability Current
IncreaseDecreaseContractWithCustomerLiabilityCurrent
0 usd
inhibrx Increase Decrease Contract With Customer Liability Current
IncreaseDecreaseContractWithCustomerLiabilityCurrent
-47000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-120408000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-82243000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2334000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
340000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2334000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-340000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
71678000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1210000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
71678000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1210000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-51064000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-81373000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
277924000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
273865000 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
226860000 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
192492000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
207000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
582000 usd
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassification of Prior Year Presentation</span></div>Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on the reported results of operations.
CY2024Q2 inhibrx Merger Exchange Ratio Pro Rate Basis Percentage
MergerExchangeRatioProRateBasisPercentage
0.92
CY2024Q1 inhibrx Merger Exchange Ratio Pro Rate Basis Percentage
MergerExchangeRatioProRateBasisPercentage
0.92
CY2024Q2 inhibrx Share Based Payment Arrangement Option Exercise Price Range Settled Cash Price Per Common Share
ShareBasedPaymentArrangementOptionExercisePriceRangeSettledCashPricePerCommonShare
30.00
CY2024Q2 inhibrx Share Based Payment Arrangement Option Exercise Price Range Settled Contingent Value Right Per Common Share
ShareBasedPaymentArrangementOptionExercisePriceRangeSettledContingentValueRightPerCommonShare
1 right
CY2024Q2 inhibrx Share Based Payment Arrangement Option Exercise Price Range Settled Contingent Value Right Cash Per Common Share
ShareBasedPaymentArrangementOptionExercisePriceRangeSettledContingentValueRightCashPerCommonShare
5.00
CY2024Q2 inhibrx Merger Exchange Ratio
MergerExchangeRatio
4
CY2024Q2 inhibrx Merger Ownership Percentage
MergerOwnershipPercentage
0.08
CY2024Q1 us-gaap Business Combination Consideration Transferred Other1
BusinessCombinationConsiderationTransferredOther1
68000000 usd
us-gaap Nonmonetary Transaction Gain Loss Recognized On Transfer
NonmonetaryTransactionGainLossRecognizedOnTransfer
2000000000.0 usd
CY2024Q2 us-gaap Nonmonetary Transaction Gain Loss Recognized On Transfer
NonmonetaryTransactionGainLossRecognizedOnTransfer
2000000000.0 usd
CY2024Q2 us-gaap Nonmonetary Transaction Gain Loss Recognized On Transfer
NonmonetaryTransactionGainLossRecognizedOnTransfer
2021498000 usd
us-gaap Nonmonetary Transaction Gain Loss Recognized On Transfer
NonmonetaryTransactionGainLossRecognizedOnTransfer
2021498000 usd
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-14400000 usd
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
226900000 usd
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of these unaudited condensed consolidated financial statements in conformity with GAAP requires the Company to make estimates and judgments that affect the reported amounts of assets, liabilities, revenue and expense and the disclosure of contingent assets and liabilities in the Company’s financial statements and accompanying notes. The Company’s most significant estimates relate to evaluation of whether revenue recognition </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">criteria have been met, accounting for development work and preclinical studies and clinical trials, determining the assumptions used in measuring stock-based compensation, the incremental borrowing rate estimated in relation to the Company’s operating lease, and valuation allowances for the Company’s deferred tax assets. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. The Company’s actual results may differ from these estimates under different assumptions or conditions.</span></div>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits by the Federal Deposit Insurance Corporation, or FDIC, of up to $250,000. The Company’s cash management and investment policy limits investment instruments to investment-grade securities with the objective to preserve capital and to maintain liquidity until the funds can be used in operations. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash balances due to the financial condition of the depository institutions in which those deposits are held.</span></div>
CY2024Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
0 usd
CY2023Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
0 usd
CY2024Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
188000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
366000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1664000 shares
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
CY2024Q2 inhibrx Clinical Trails Prepaid Expense Current
ClinicalTrailsPrepaidExpenseCurrent
5910000 usd
CY2023Q4 inhibrx Clinical Trails Prepaid Expense Current
ClinicalTrailsPrepaidExpenseCurrent
5409000 usd
CY2024Q2 inhibrx Clinical Drug Substance And Product Manufacturing Prepaid Expense Current
ClinicalDrugSubstanceAndProductManufacturingPrepaidExpenseCurrent
4931000 usd
CY2023Q4 inhibrx Clinical Drug Substance And Product Manufacturing Prepaid Expense Current
ClinicalDrugSubstanceAndProductManufacturingPrepaidExpenseCurrent
9888000 usd
CY2024Q2 inhibrx Prepaid License Current
PrepaidLicenseCurrent
1116000 usd
CY2023Q4 inhibrx Prepaid License Current
PrepaidLicenseCurrent
728000 usd
CY2024Q2 inhibrx Outside Research And Development Services Prepaid Expense Current
OutsideResearchAndDevelopmentServicesPrepaidExpenseCurrent
887000 usd
CY2023Q4 inhibrx Outside Research And Development Services Prepaid Expense Current
OutsideResearchAndDevelopmentServicesPrepaidExpenseCurrent
265000 usd
CY2024Q2 us-gaap Other Assets Current
OtherAssetsCurrent
966000 usd
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
366000 usd
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
13810000 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
16656000 usd
CY2024Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
15081000 usd
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
13106000 usd
CY2024Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
7476000 usd
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6687000 usd
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7605000 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6419000 usd
CY2024Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
475000 usd
CY2023Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
295000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
836000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
589000 usd
CY2024Q2 inhibrx Accrued Clinical Trials Current
AccruedClinicalTrialsCurrent
12215000 usd
CY2023Q4 inhibrx Accrued Clinical Trials Current
AccruedClinicalTrialsCurrent
9224000 usd
CY2024Q2 inhibrx Accrued Clinical Drug Substance And Product Manufacturing Current
AccruedClinicalDrugSubstanceAndProductManufacturingCurrent
4538000 usd
CY2023Q4 inhibrx Accrued Clinical Drug Substance And Product Manufacturing Current
AccruedClinicalDrugSubstanceAndProductManufacturingCurrent
22805000 usd
CY2024Q2 inhibrx Accrued Outside Research And Development Other Current
AccruedOutsideResearchAndDevelopmentOtherCurrent
1217000 usd
CY2023Q4 inhibrx Accrued Outside Research And Development Other Current
AccruedOutsideResearchAndDevelopmentOtherCurrent
1129000 usd
CY2024Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4508000 usd
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
6506000 usd
CY2024Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
959000 usd
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
780000 usd
CY2024Q2 inhibrx Accrued Interest Expense Current
AccruedInterestExpenseCurrent
0 usd
CY2023Q4 inhibrx Accrued Interest Expense Current
AccruedInterestExpenseCurrent
2348000 usd
CY2024Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
423000 usd
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
503000 usd
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
23860000 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
43295000 usd
CY2024Q2 inhibrx Debt Instrument Balloon Payment Write Off
DebtInstrumentBalloonPaymentWriteOff
18000000 usd
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000 shares
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
15000000 shares
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
14475904 shares
CY2024Q2 inhibrx Merger Exchange Ratio
MergerExchangeRatio
4
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
13316140 shares
CY2024Q2 inhibrx Merger Ownership Percentage
MergerOwnershipPercentage
0.08
CY2024Q2 us-gaap Stock Or Units Available For Distributions
StockOrUnitsAvailableForDistributions
1157926 shares
CY2024Q2 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
1838 shares
CY2024Q2 us-gaap Stock Issued During Period Shares Conversion Of Convertible Securities
StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
2746454 shares
CY2024Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.0001
CY2024Q2 inhibrx Class Of Warrant Or Right Contingent Value Right Per Warrant
ClassOfWarrantOrRightContingentValueRightPerWarrant
1 right
CY2024Q2 inhibrx Class Of Warrant Or Right Contingent Value Right Per Warrant Value
ClassOfWarrantOrRightContingentValueRightPerWarrantValue
5.00
CY2024Q2 inhibrx Merger Exchange Ratio
MergerExchangeRatio
4
CY2024Q2 inhibrx Class Of Warrant Or Right Purchase Price Of Warrants Or Rights
ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights
991849 shares
CY2024Q2 inhibrx Class Of Warrant Or Right Contingent Value Right Per Warrant
ClassOfWarrantOrRightContingentValueRightPerWarrant
1 right
CY2024Q2 inhibrx Class Of Warrant Or Right Contingent Value Right Per Warrant Value
ClassOfWarrantOrRightContingentValueRightPerWarrantValue
5.00
CY2024Q2 inhibrx Merger Exchange Ratio
MergerExchangeRatio
4
CY2024Q2 inhibrx Class Of Warrant Or Right Cancelled Threshold Exercise Price
ClassOfWarrantOrRightCancelledThresholdExercisePrice
35.00
CY2024Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
0 shares
CY2024Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
4992000 shares
CY2023Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
13789000 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
65300000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
1300000 usd
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
42500000 usd
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
13800000 usd
CY2024Q2 inhibrx Share Based Payment Arrangement Option Exercise Price Range Settled Exercise Price
ShareBasedPaymentArrangementOptionExercisePriceRangeSettledExercisePrice
35.00
CY2024Q2 inhibrx Share Based Payment Arrangement Option Exercise Price Range Settled Cash Price Per Common Share
ShareBasedPaymentArrangementOptionExercisePriceRangeSettledCashPricePerCommonShare
30.00
CY2024Q2 inhibrx Share Based Payment Arrangement Option Exercise Price Range Settled Contingent Value Right Per Common Share
ShareBasedPaymentArrangementOptionExercisePriceRangeSettledContingentValueRightPerCommonShare
1 right
CY2024Q2 inhibrx Share Based Payment Arrangement Option Exercise Price Range Settled Contingent Value Right Cash Per Common Share
ShareBasedPaymentArrangementOptionExercisePriceRangeSettledContingentValueRightCashPerCommonShare
5.00
CY2024Q2 inhibrx Class Of Warrant Or Right Cancelled Threshold Exercise Price
ClassOfWarrantOrRightCancelledThresholdExercisePrice
35.00
CY2024Q2 inhibrx Class Of Warrant Or Right Cancelled Threshold Exercise Price
ClassOfWarrantOrRightCancelledThresholdExercisePrice
35.00
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1800000 usd
CY2024Q1 inhibrx Merger Exchange Ratio Pro Rate Basis Percentage
MergerExchangeRatioProRateBasisPercentage
0.92
CY2024Q2 inhibrx Merger Ownership Percentage
MergerOwnershipPercentage
0.08
CY2024Q2 us-gaap Stock Or Units Available For Distributions
StockOrUnitsAvailableForDistributions
1157926 shares
us-gaap Related Party Transaction Amounts Of Transaction
RelatedPartyTransactionAmountsOfTransaction
200000 usd
CY2024Q2 us-gaap Related Party Transaction Amounts Of Transaction
RelatedPartyTransactionAmountsOfTransaction
200000 usd
CY2017Q3 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P7Y
CY2017Q3 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P5Y
CY2017Q3 inhibrx Lessee Operating Lease Initial Base Rent Expense Per Month
LesseeOperatingLeaseInitialBaseRentExpensePerMonth
100000 usd
CY2017Q3 inhibrx Lessee Operating Lease Annual Escalations
LesseeOperatingLeaseAnnualEscalations
0.02
CY2019Q2 inhibrx Lessee Operating Lease Initial Base Rent Expense Per Month
LesseeOperatingLeaseInitialBaseRentExpensePerMonth
30000 usd
CY2019Q2 inhibrx Lessee Operating Lease Annual Escalations
LesseeOperatingLeaseAnnualEscalations
0.02
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2011000 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2952000 usd
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2171000 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2063000 usd
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1110000 usd
CY2024Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
2171000 usd
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
3173000 usd
CY2024Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
800000 usd
CY2023Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
800000 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
1600000 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
1700000 usd
CY2024Q2 inhibrx Operating Lease Payments Included In Measurement Of Lease Liability
OperatingLeasePaymentsIncludedInMeasurementOfLeaseLiability
600000 usd
CY2023Q2 inhibrx Operating Lease Payments Included In Measurement Of Lease Liability
OperatingLeasePaymentsIncludedInMeasurementOfLeaseLiability
500000 usd
inhibrx Operating Lease Payments Included In Measurement Of Lease Liability
OperatingLeasePaymentsIncludedInMeasurementOfLeaseLiability
1100000 usd
inhibrx Operating Lease Payments Included In Measurement Of Lease Liability
OperatingLeasePaymentsIncludedInMeasurementOfLeaseLiability
1100000 usd
CY2024Q2 us-gaap Lessee Operating Lease Remaining Lease Term
LesseeOperatingLeaseRemainingLeaseTerm
P1Y
CY2023Q4 us-gaap Lessee Operating Lease Remaining Lease Term
LesseeOperatingLeaseRemainingLeaseTerm
P1Y6M
CY2024Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.082
CY2023Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.082
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
1132000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1137000 usd
CY2024Q2 inhibrx Lessee Operating Lease Liability To Be Paid After Year One
LesseeOperatingLeaseLiabilityToBePaidAfterYearOne
0 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
2269000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
98000 usd
CY2024Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
2171000 usd
CY2024Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
0002007919-24-000029-index-headers.html Edgar Link pending
0002007919-24-000029-index.html Edgar Link pending
0002007919-24-000029.txt Edgar Link pending
0002007919-24-000029-xbrl.zip Edgar Link pending
exhibit311q22024.htm Edgar Link pending
exhibit312q22024.htm Edgar Link pending
exhibit321q22024.htm Edgar Link pending
exhibit322q22024.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
image_0.jpg Edgar Link pending
inhibrx-20240630.htm Edgar Link pending
inhibrx-20240630.xsd Edgar Link pending
inhibrx-20240630_g1.jpg Edgar Link pending
inhibrx-20240630_g2.jpg Edgar Link pending
inhibrxbiosciencesnon-empl.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
inhibrx-20240630_cal.xml Edgar Link unprocessable
inhibrx-20240630_def.xml Edgar Link unprocessable
inhibrx-20240630_lab.xml Edgar Link unprocessable
inhibrx-20240630_pre.xml Edgar Link unprocessable
inhibrx-20240630_htm.xml Edgar Link completed
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending